VELOXIS PHARMACEUTICALS A/S: Financial statements 2016
CVR: 26527767
Source: annual report 2016, Danish Business Authority
01/01/2016 – 31/12/2016
VELOXIS PHARMACEUTICALS A/S (CVR 26527767) has filed annual accounts for 2016. In 2016, the company reported revenue of USD 9,194,000 and a net result of USD -10,135,000 compared with DKK -176,106,000 the year before. That is a decrease of 35% compared with the year before. The profit margin was -110.2%. Equity in the 2016 report amounted to USD 10,195,000. The solvency ratio was 34.1%.
- Revenue
- USD 9,194,000
- Gross Profit
- USD 6,175,000
- Profit/Loss
- USD -10,135,000
- Equity
- USD 10,195,000
- Total Assets
- USD 29,884,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2016 | 9.2M USD | 6.2M USD | -10.1M USD | 10.2M USD | - |
| 2015 | 14.2M | -989K | -176.1M | 89.7M | - |
| 2014 | 123.4M | 120.1M | -36.3M | 253.2M | - |
Official annual report
Find more companies like VELOXIS PHARMACEUTICALS A/S
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2016
VELOXIS PHARMACEUTICALS A/S has published its interim report for the period January 1, 2016 to June 30, 2016.
As of July 26, 2016, Lars Kåre Viksmoen has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of July 26, 2016, Paul Kevin Wotton has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of July 26, 2016, Robert Samuel Radie has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of July 26, 2016, Thomas Peter Dyrberg has left the board of directors of VELOXIS PHARMACEUTICALS A/S.
VELOXIS PHARMACEUTICALS A/S has published its interim report for the period January 1, 2016 to March 31, 2016.
VELOXIS PHARMACEUTICALS A/S has published its annual report for 2015. Revenue came to DKK 14,150,000, and the net result was DKK -176,106,000.
As of April 7, 2016, Johnny Stilou has stepped down as økonomidirektør of VELOXIS PHARMACEUTICALS A/S.
As of April 6, 2016, Mette Kirstine Agger has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
As of April 6, 2016, Thomas Peter Dyrberg has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.
About VELOXIS PHARMACEUTICALS A/S
VELOXIS PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Nordhavn, founded in 2002. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named LIFECYCLE PHARMA A/S and PHAROTECH A/S. The management consists of Daisuke Matsuo. The board consists of Keigo Nakatsukasa (chair), Daisuke Matsuo and Kenro Yuzaki. The company is owned by Asahi Kasei Corporation. The company has 1 employee (2022). In 2026, the company reported a net result of DKK -1,553,000. Equity in the 2026 report amounted to DKK 611,587,000.